COVID-19 Symptoms in 2025: Current Medical Understanding

As of December 2025, medical professionals continue to refine their understanding of COVID-19 symptoms as the virus evolves and populations develop varying levels of immunity through vaccination and prior infections. The clinical presentation of COVID-19 has shown notable shifts since the initial pandemic strain.

Primary Symptoms in 2025

The most commonly reported symptoms of COVID-19 in 2025 include:

Sore throat or pharyngitis (reported in approximately 58% of cases)
Headache (52% of cases)
Persistent cough (49% of cases)
Fatigue or malaise (47% of cases)
Nasal congestion or runny nose (44% of cases)
Muscle aches (39% of cases)
Fever or chills (37% of cases)

Notably, the loss of taste or smell, which was a hallmark symptom in early variants, is now reported in fewer than 15% of cases, according to data from the World Health Organization's December 2025 epidemiological report.

Variant-Specific Symptom Presentation

The predominant circulating variants in December 2025, including KP.2 and its sub-lineages, appear to primarily affect the upper respiratory tract rather than causing severe lower respiratory symptoms that characterized earlier variants. This shift has resulted in symptoms more closely resembling those of common colds or influenza.

Atypical Presentations

Medical professionals have identified several atypical presentations in 2025:

Neurological symptoms: "Brain fog," memory issues, and concentration difficulties continue to be reported, particularly in individuals with long COVID
Gastrointestinal disturbances: Nausea, vomiting, and diarrhea occur in approximately 12% of cases
Cardiovascular effects: Some patients experience palpitations or chest pain, warranting cardiac evaluation in persistent cases

Testing Recommendations

Health authorities recommend testing for COVID-19 when experiencing any combination of the above symptoms, particularly if accompanied by known exposure to confirmed cases or in vulnerable populations including the elderly, immunocompromised individuals, and those with chronic conditions.